Aurinia Pharmaceuticals (AUPH) Earnings Date
The next earnings date for Aurinia Pharmaceuticals (AUPH) is expected by Feb 11, 2027, per the data provider's calendar.
- Next earnings date
- Feb 11, 2027
- expected by · quarter ending Dec '26
- Consensus EPS
- $0.21
- Dec '26 quarter · 3 analysts
- Consensus revenue
- $85.1M
- Dec '26 quarter · 3 analysts
- Latest stored quarter
- EPS 0.23
- revenue $83.7M · reported Oct 30, 2026
Does this company deliver against its own promises? Earnings are a check on the thesis, not a catalyst to chase.
All 2 scored quarters beat, yet the stock still fell after 1 of them (Oct 30, 2026). The market prices the whole print, not the headline beat. Chasing earnings pops is a coin flip.
| Report | Est EPS | Act EPS | Surprise | Est rev | Act rev | Rev surp. | Reaction |
|---|---|---|---|---|---|---|---|
| Oct 30, 20268-K, before open · 8:03 am ET | 0.22 | 0.23 | +4.5% | $83.6M | $83.7M | +0.1% | −3.3%release day |
| Aug 6, 20268-K, before open · 8:03 am ET | 0.24 | 0.28 | +16.7% | $80.4M | $83.2M | +3.4% | +6.2%release day |
| May 7, 20268-K, before open · 8:22 am ET | — | 0.25 | — | — | $77.7M | — | −6.8%release day |
| Feb 26, 20268-K, before open · 6:02 am ET | — | 1.52 | — | — | $77.1M | — | −3.2%release day |
| Nov 4, 20258-K, before open · 8:00 am ET | — | 0.23 | — | — | $73.5M | — | +8.4%release day |
| Jul 31, 20258-K, before open · 6:01 am ET | — | 0.16 | — | — | $70.0M | — | +2.2%release day |
| May 12, 20258-K, before open · 6:02 am ET | — | 0.16 | — | — | $62.5M | — | +1.5%release day |
| Feb 4, 2025 E | — | 0.01c | — | — | $59.9M | — | —estimated date |
Estimate-vs-actual scoring began Jul 2026 and is still accruing: 2 of the 8 quarters above carry a scored estimate. We never backfill an estimate we didn't observe.
E marks a report date we estimated from the fiscal period end, because we found no results release and no usable filing date for that quarter. Those rows show no reaction: a move measured from a day we guessed is not a reaction to the release, and we would rather leave it blank than publish it.
c Computed by Tenet. The company's diluted figure is not in our data feed for this period, so this is net income attributable to common shareholders divided by the larger of the weighted basic and diluted share counts.
| Measure | Dec '26 | Mar '27 | FY26 | FY27 |
|---|---|---|---|---|
| No. of analysts | 3 | 2 | 4 | 4 |
| Avg estimate | 0.21 | 0.19 | 0.97 | 1.16 |
| Low estimate | 0.21 | 0.17 | 0.93 | 1.12 |
| High estimate | 0.22 | 0.21 | 1.00 | 1.20 |
| Year-ago EPS | 1.52 | 0.25 | 2.07 | 0.97E |
| Implied growth | −85.9% | −24.0% | −53.1% | +19.6% |
| Measure | Dec '26 | Mar '27 | FY26 | FY27 |
|---|---|---|---|---|
| No. of analysts | 3 | 2 | 3 | 4 |
| Avg estimate | $85.1M | $83.0M | $329.2M | $385.7M |
| Low estimate | $84.1M | $80.9M | $316.3M | $370.6M |
| High estimate | $86.2M | $85.0M | $364.6M | $427.1M |
| Year-ago revenue | $77.1M | $77.7M | $283.1M | $329.2ME |
| Implied growth | +10.4% | +6.7% | +16.3% | +17.2% |
| Snapshot age | Dec '26, period ending Dec 30, 2026 | Mar '27, period ending Mar 30, 2027 | FY26, period ending Dec 31, 2026 | FY27, period ending Dec 31, 2027 |
|---|---|---|---|---|
| Current estimate | 0.21 | 0.19 | 0.97 | 1.16 |
| 7 days ago | 0.21 | — | 0.97 | 1.16 |
| 30 days ago | 0.20 | — | 0.94 | 1.18 |
| 60 days ago | 0.20 | — | 0.94 | 1.18 |
| 90 days ago | 0.22 | — | 0.96 | 1.23 |
Estimate history accrues from our nightly snapshots. The 7/30/60/90-day rows fill in as tracking continues. Each column follows one fiscal period back through our snapshots; a dash means we had not recorded that period at that age. A rising bar makes a beat streak more meaningful; a falling one manufactures beats.
Dec '26 quarter consensus moved $0.22 → $0.21 over 90 tracked days, the same quarter at both ends. Per-analyst up/down revision counts aren't in our data feed. We show the bar's actual movement instead of guessing.
Common questions
When does Aurinia Pharmaceuticals report earnings next?
Aurinia Pharmaceuticals' next earnings date is expected by Feb 11, 2027, per the data provider's calendar.
What were Aurinia Pharmaceuticals' latest quarterly earnings?
Aurinia Pharmaceuticals reported diluted EPS of 0.23 and revenue of $83.7M on Oct 30, 2026.
How did Aurinia Pharmaceuticals' stock move after its last earnings report?
Aurinia Pharmaceuticals moved −3.3% in the session after its Oct 30, 2026 report.

